Population Pharmacokinetics and Exposure‐Response Analyses for Ubrogepant Efficacy and Safety in the Acute Treatment of Migraine: Analysis of Phase 1–3 Studies

Documenti analoghi

• Exposure–Response Modeling of Monthly Migraine Days for Efficacy of Atogepant in Patients With Episodic or Chronic Migraine
  di: Louisa Schlachter, et al.
  Pubblicazione: (2025)
• A 2‐Part, Open‐Label, Phase 1 Bioequivalence and Food‐Effect Study of Ubrogepant in Healthy Adult Participants
  di: Ramesh Boinpally, et al.
  Pubblicazione: (2025)
• Pharmacokinetics and Exposure–Response Analyses to Support Dose Selection of Upadacitinib in Crohn's Disease
  di: Sumit Bhatnagar, et al.
  Pubblicazione: (2024)
• Pharmacokinetics and Safety of Atogepant Co‐administered with Quinidine Gluconate in Healthy Participants: A Phase 1, Open‐Label, Drug‐Drug Interaction Study
  di: Ramesh Boinpally, et al.
  Pubblicazione: (2024)
• Population Pharmacokinetics of Valemetostat and Exposure–Response Analyses of Efficacy and Safety in Patients with Relapsed/Refractory Peripheral T–Cell Lymphoma
  di: Hiroyuki Inoue, et al.
  Pubblicazione: (2025)